A Single-Pot Template Reaction Towards a Manganese-Based T₁ Contrast Agent.

Area of Science:

• Magnetic Resonance Imaging (MRI)
• Inorganic Chemistry
• Biomedical Engineering

Background:

• Manganese-based contrast agents (MnCAs) are explored as alternatives to gadolinium-based contrast agents (GdCAs).
• Existing MnCAs face challenges with kinetic lability and complex synthesis, limiting clinical use.
• Development of stable and effective MnCAs is crucial for advancing MRI technology.

Purpose of the Study:

• To develop a novel manganese-based contrast agent, MnL, using an innovative synthetic strategy.
• To characterize the key physicochemical properties of MnL in vitro.
• To evaluate the in vivo performance and safety profile of MnL for MRI applications.

Main Methods:

• A single-pot template synthetic strategy was employed to synthesize the MnCA, MnL.
• Physicochemical properties, including r1 relaxivity, were measured in vitro at various magnetic field strengths.
• In vivo studies assessed MnL's pharmacokinetic profile, biodistribution, and renal excretion compared to a commercial GdCA.

Main Results:

• MnL exhibits optimized r1 relaxivities across a range of magnetic fields (20-400 MHz).
• MnL shows enhanced relaxivity upon binding to bovine serum albumin (BSA), with a binding affinity (Ka) of 4.2×10^3 M^-1.
• In vivo, MnL is cleared intact via renal excretion with a prolonged blood half-life compared to Magnevist.

Conclusions:

• The single-pot synthesis offers an efficient route to a novel MnCA, MnL.
• MnL possesses favorable relaxivity and pharmacokinetic properties, suggesting its potential as an MRI contrast agent.
• MnL demonstrates promise as a safe and effective alternative to current GdCAs in clinical MRI.